Oncternal commences phase 2 trial of cirmtuzumab-ibrutinib combination
Category: #healthcare  By Akshay Kedari  Date: 2019-08-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oncternal commences phase 2 trial of cirmtuzumab-ibrutinib combination

Under the phase 2 trial approximately 90 patients with CLL will receive either ibrutinib or ibrutinib coupled with cirmtuzumab

Oncternal Therapeutics, a biotechnology company, has reportedly announced opening of enrollment for patients suffering from chronic lymphocytic leukemia (CCL) for its Phase 2 study of cirmtuzumab which is a ROR1- targeted monoclonal antibody, in a combination with ibrutinib.

Reportedly, favorable outcomes from the Part 1 dose-finding as well as Part 2 dose-confirming cohorts of this study led to the decision of carrying out Phase 2 trial of the ongoing phase 1/2 CIRLL by the company. The results from the earlier studies included an interim ORR at 100% for the first 9 lymphocytic leukemia patients who completed 12 weeks of recommended dosage of cirmtuzumab and ibrutinib combo treatment in Part 2.

According to trusted sources, the company presented its data study at the annual meeting of American Society of Clinical Oncology (ASCO) stating the results from trial conducted on first 12 patients with CLL attended in Part 1 of the Phase 1 study showcasing an interim objective response rate of 91.7% for the combination of ibrutinib and cirmtuzumab. This included three patients with confirmed complete responses as well as tolerated safety profile consistent with the results seen in the treatment of ibrutinib alone.

Additionally, the results put forward during the ASCO meet were preliminary results derived from six patients who were given the treatment in separate cohort of the CRR and were diagnosed with mantle cell lymphoma (MCL). Data from this cohort will be presented at medical conferences in the future.

Apparently, a patient suffering from MCL had relapsed due to an allogenic stem cell transplant and experienced a complete response after undergoing cirmtuzumab plus ibrutinib treatment for 3 months, including resolution of large mediastinal mass. Hence, the CR is durable and has been confirmed after giving 6.9 and 11 months of cirmtuzumab plus ibrutinib treatment.

Citing reports, the CIRLL clinical study is supported by a grant extended by California Institute for Regenerative Medicines (CIRM) and will be managed in collaboration with the University of California at San Diego.

 

Source Credits: http://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-announces-opening-randomized-phase-2

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Junshi Biosciences completes enrollment for Phase I COVID-19 study
Junshi Biosciences completes enrollment for Phase I COVID-19 study
By Akshay Kedari

  JS016 is apparently unique to the SARS-CoV-2 surface spike protein receptor-binding domain...

Hinterland Metals inks letter of intent to procure Novamind Ventures
Hinterland Metals inks letter of intent to procure Novamind Ventures
By Akshay Kedari

Hinterland Metals Inc., a junior mineral exploration firm based in Canada, has reportedly announced ...

Walmart to turn parking lots into drive-in theaters with Tribeca
Walmart to turn parking lots into drive-in theaters with Tribeca
By Akshay Kedari

American retail giant, Walmart Inc. has recently announced that it will be collaborating with Tribec...